Category: us corporate news

us corporate news

European Commission Approves Once-Every-Four-Weeks Elfabrio® (Pegunigalsidase Alfa) Dosing for Fabry Disease, Reducing Treatment Burden for Adults

Minichart

March 9, 2026

Protalix & Chiesi Announce Major EU Approval for Elfabrio ...

Continue Reading 0

us corporate news

Strategy Inc (Formerly MicroStrategy) Announces ATM Offering Update and Bitcoin Holdings Disclosure in March 2026 8-K Filing

Minichart

March 9, 2026

Strategy Inc. (formerly MicroStrategy) Files Form 8-K: ATM O...

Continue Reading 0

us corporate news

Genesis Energy, L.P. Form 8-K Filing Details for March 4, 2026 – Company Information, Exchange, and Compliance Disclosures

Minichart

March 9, 2026

Genesis Energy, L.P. Announces Entry into New \$900 Million ...

Continue Reading 0

us corporate news

Signing Day Sports and BlockchAIn Announce Modular AI Data Center Strategy and Multi-Gigawatt Expansion with PDM Collaboration

Minichart

March 9, 2026

Signing Day Sports & BlockchAIn Inc. Strategic Update: Modul...

Continue Reading 0

us corporate news

Unusual Machines Reports 101% Revenue Growth in 2025, Expands NDAA-Compliant Drone Component Operations and Strengthens Financial Position

Minichart

March 9, 2026

Unusual Machines Reports Transformative 2025 Results: Strong...

Continue Reading 0

us corporate news

Xilio Therapeutics Advances Masked Immuno-Oncology Therapies with Robust Pipeline, Strategic Partnerships, and Strong Financials (2026 Update)

Minichart

March 9, 2026

Xilio Therapeutics Unveils Robust Pipeline Progress and Stro...

Continue Reading 0

us corporate news

Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment

Minichart

March 9, 2026

Keros Therapeutics Partners with Healey & AMG Center for ALS...

Continue Reading 0

us corporate news

MBX Biosciences to Initiate Phase 3 Trial of Once-Weekly Canvuparatide for Hypoparathyroidism Following Successful FDA End-of-Phase 2 Meeting

Minichart

March 9, 2026

MBX Biosciences Announces Key FDA Milestone and Phase 3 Plan...

Continue Reading 0

us corporate news

Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026

Minichart

March 9, 2026

Lyell Immunopharma Appoints New Chief Financial and Business...

Continue Reading 0

us corporate news

Byrna Technologies Reports Preliminary Q1 2026 Revenues of $29 Million – Financial Highlights and Company Information

Minichart

March 9, 2026

Byrna Technologies Inc. - Detailed Investor Article on Q1 20...

Continue Reading 0